Elizabeth Bhatt
Director/Miembro de la Junta en EFFECTOR THERAPEUTICS, INC. .
Fortuna: 578 $ al 31/05/2024
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Stephen Worland | M | 66 | 12 años | |
Brian Gallagher | M | 54 | 4 años | |
Jeffrey Finer | M | - |
Septerna, Inc.
Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | - |
Christopher Ehrlich | M | 54 | 3 años | |
Andrew Dickinson | M | 54 | 8 años | |
Barbara Klencke | M | 66 | 3 años | |
Michael Byrnes | M | 47 | 4 años | |
Kelly Kramer | F | 56 | 8 años | |
Kristen Harrington-Smith | F | 51 | 2 años | |
Caroline Loewy | F | 58 | 1 años | |
Jeffrey Tong | M | 48 |
Septerna, Inc.
Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | - |
Mayank J. Gandhi | M | 47 | 2 años | |
Linda Higgins | M | 62 | 14 años | |
Jennifer Doudna | M | 60 | - | |
Abraham Bassan | M | 39 |
Septerna, Inc.
Septerna, Inc. Pharmaceuticals: MajorHealth Technology Septerna, Inc. is a biotechnology company located in an undisclosed location. The American company is focused on developing novel, oral small molecule drugs that target the entire class of G protein-coupled receptors (GPCRs). The company's Native Complex™ platform allows for the rapid application of new technologies for industrial-scale drug discovery to address both validated GPCRs and many GPCRs that have been undruggable and unexploited to date. Septerna is building a pipeline of GPCR-targeted, oral small molecule drug candidates, led by its program targeting the parathyroid hormone 1 receptor (PTH1R) for the treatment of hypoparathyroidism. The company was founded in 2022 by scientific founders who have made groundbreaking GPCR discoveries, including Patrick Sexton, Arthur Christopoulos, Robert Joseph Lefkowitz, and Jeffrey T. Finer. Jeffrey T. Finer has been the CEO since incorporation. | 3 años |
Mark Densel | M | - | 6 años | |
Michael Hodges | M | - | - | |
Douglas Warner | M | 52 | 2 años | |
Robert Cook | M | 65 | 12 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 99 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Elizabeth Bhatt
- Red Personal